GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Deferred Policy Acquisition Costs

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Deferred Policy Acquisition Costs


View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111
Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.